Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: upper tract urothelial carcinoma for whom extirpative surgery is planned
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In this Clinical Consultation Guide, we highlight prospective studies supporting the use of preoperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma for whom extirpative surgery is planned.
In this Clinical Consultation Guide, we highlight prospective studies supporting the use of preoperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma for whom extirpa
APA
Fletcher SA, Singla N, Hoffman-Censits J (2026). Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer.. European urology focus, 12(1), 19-21. https://doi.org/10.1016/j.euf.2025.07.014
MLA
Fletcher SA, et al.. "Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer.." European urology focus, vol. 12, no. 1, 2026, pp. 19-21.
PMID
40841249 ↗
Abstract 한글 요약
In this Clinical Consultation Guide, we highlight prospective studies supporting the use of preoperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma for whom extirpative surgery is planned.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.